Semaglutide

Tirzepatide, a dual Glucose-dependent Insulinotropic Polypeptide (GIP) and Glucagon-Like Peptide-1 (GLP-1) receptor agonist. Tirzepatide was first approved by the FDA for type 2 diabetes in May 2022 and subsequently for obesity in November 2023, and…

BACKGROUND AND AIMS: Semaglutide, a once-weekly injectable glucagon-like peptide, showed double-digit weight reduction with an acceptable safety profile in clinical trials and real-world studies. The efficacy and safety of non-comparable biotherapeut…

BACKGROUND: We previously reported reductions in weight and cardiometabolic risk factors in people with human immunodeficiency virus (PWH) receiving semaglutide; here, we explored the durability of these changes after treatment cessation. METHODS: AC…

BACKGROUND: Metabolic dysfunction-associated steatotic liver disease (MASLD) is closely linked to obesity and insulin resistance, and sustained weight loss is associated with histological improvement. Whether different obesity-management modalities e…

BACKGROUND: The escalating use of Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is reshaping pharmaceutical consumption patterns and posing unprecedented challenges to healthcare systems worldwide. This study analyzes the landscape of GLP-1 R…

Semaglutide, marketed as Ozempic, Wegovy and Rybelsus, has rapidly become one of the most prominent medications of recent years. Initially approved in 2021 for type 2 diabetes in adults, semaglutide is now authorised for obesity management in adults…

We report a rare drugs adverse effect of a GLP1-RA, presenting as severe gastric stasis, eosinophilic duodenitis, and high bowel obstruction. The patient, treated with oral semaglutide for type 2 diabetes and obesity, developed progressive upper gast…

The introduction of incretin-based therapy has brought a significant transformation in the treatment of type 2 diabetes and obesity. It works by augmenting natural incretin hormones to enhance insulin secretion and suppress glucagon release in a gluc…

Type 2 diabetes mellitus (T2DM) is characterized not only by chronic hyperglycemia but also by profound adipose tissue dysfunction, including impaired lipid handling, low-grade inflammation, mitochondrial dysfunction, and extracellular matrix (ECM) r…

OBJECTIVE: This debate paper aims to examine the effects of glucagon-like peptide-1 receptor agonists (GLP-1 RAs), whose use in obesity and diabetes management has rapidly expanded, on fertility, contraceptive efficacy, and pregnancy outcomes in repr…

BACKGROUND/AIMS: Non-invasive test (NIT)-based assessment of eligibility and treatment response with semaglutide is needed to inform clinical practice guidance. Therefore, utilising a randomised, placebo-controlled study design, we evaluated the util…

This report describes a female patient in her 60s with an immune-mediated necrotising myopathy (IMNM) occurring after semaglutide use. She was found to have progressive dysphagia, dysphonia, proximal muscle weakness and creatine kinase elevation over…

Semaglutide is a glucagon-like peptide 1 (GLP-1) agonist that has found widespread popularity as a weight loss product. Initially developed as a treatment for diabetes, the drug acts to stimulate the secretion of insulin, as well as suppress appetite…

Metabolic dysfunction associated steatotic liver disease (MASLD) affects nearly one-third of adults worldwide, particularly among individuals with obesity or type 2 diabetes, and in 10-30% progresses to metabolic dysfunction associated steatohepatiti…

Semaglutide, a long-acting glucagon-like peptide-1 receptor agonist (GLP-1RA), is widely used in the treatment of patients with type 2 diabetes mellitus and obesity. A sensitive and reliable quantification method is essential for bioanalysis of semag…

AIMS: To analyse prescribing trends in antidiabetic agents stratified by background characteristics among individuals with type 2 diabetes. MATERIALS AND METHODS: This retrospective study used a large-scale database between 2015 and 2024 in Japan. Ad…